Rare diseases
Investigational molecules
Locations
20 Overland Street Suite 520, 02215-3336, United States
Mediar Therapeutics Inc. focuses on clinical research in idiopathic pulmonary fibrosis, a chronic interstitial lung disease marked by progressive scarring of the lungs and declining respiratory function.
The sponsor’s research activity is centered on outcomes relevant to breathing capacity and the preservation of lung function in people living with fibrotic lung disease.
Mediar Therapeutics Inc. runs clinical trials in conditions such as Idiopathic pulmonary fibrosis, Systemic scleroderma, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Belgium
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
